Obese seniors and diabetics are more resistant to antidepressants

In a study published in the Journal of the American Geriatrics Society, researchers make a connection between obesity, diabetes, metabolic syndrome, age, and resistance to treatments against depression.

An elderly person with a metabolic syndrome (overweight, diabetes, hypertension, gout) is more resistant to antidepressants. These are the results of a study published in the Journal of the American Geriatrics Society.
Older people with major depressive disorder may suffer from thought disorders. The daily is harder to manage, care too. Elderly people with depression also have a higher risk of death.
Suffering from depression and suffering from diabetes does not mix well.

Metabolic syndrome, what is it?

The metabolic syndrome, also called syndrome X, is not really a disease. It is a set of physiological disorders (overweight, abnormal blood glucose and lipid levels, high blood pressure, high uric acid) that increase the risk of type 2 diabetes, heart disease or stroke ( AVC).
The metabolic syndrome is promoted by lack of physical activity, sedentary lifestyle, obesity and poor diet. To avoid it, it is necessary to adopt a healthy lifestyle.

Antidepressants have less effect

To carry out this study, the researchers tested people over 60, suffering from depression and metabolic syndrome.
Each participant was treated with a reference antidepressant, venlafaxine, marketed under the name of Effexor. It is indicated for the treatment and prevention of severe cases of depression, anxiety attacks and social phobia.

Strengthen treatment

The researchers drew three conclusions about people with Syndrome X: their history of depression is older, symptoms of depression are more severe at the beginning of the study, and lastly, they take longer to respond to treatment.

Thus, for these researchers, depressed elderly people who have a metabolic syndrome must be treated with a particular strategy.

Video: Obesity & Diabetes Explained: The Overflow Phenomenon (December 2019).